PEPTRON, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71,200 KRW | -0.28% |
|
-2.06% | +76.89% |
| 2023 | Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal | MT |
| 2023 | Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023. | CI |
| Sales 2022 | 5.81B 4.2M | Sales 2023 | 3.34B 2.41M | Capitalization | 830B 599M |
|---|---|---|---|---|---|
| Net income 2022 | -15.06B -10.88M | Net income 2023 | -15.92B -11.5M | EV / Sales 2022 | 25.8 x |
| Net cash position 2022 | 8.02B 5.79M | Net Debt 2023 | 4.15B 3M | EV / Sales 2023 | 250 x |
| P/E ratio 2022 |
-10.5
x | P/E ratio 2023 |
-52
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.93% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.46% | ||
| 1 week | -1.79% | ||
| Current month | +44.68% | ||
| 1 month | +92.71% | ||
| 3 months | +200.63% | ||
| 6 months | +130.32% | ||
| Current year | +77.39% |
1 week
67 100.00
76 800.00
1 month
35 500.0076 800.00
Current year
21 100.0076 800.00
1 year
15 550.0076 800.00
3 years
7 050.0076 800.00
5 years
7 050.0076 800.00
10 years
7 050.0076 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
Min-Ho Song
CEO | Chief Executive Officer | 63 | 21-03-29 |
Ho-Il Choi
CEO | Chief Executive Officer | 58 | 97-11-20 |
Seung-Gu Jang
DFI | Director of Finance/CFO | 58 | 99-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ho-Il Choi
CEO | Chief Executive Officer | 58 | 97-11-20 |
Seung-Gu Jang
DFI | Director of Finance/CFO | 58 | 99-06-30 |
Young-Go Jung
BRD | Director/Board Member | 49 | 14-03-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +6.24% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-15 | 71,200 | -0.28% | 932 229 |
| 24-07-15 | 71,400 | -2.46% | 995,510 |
| 24-07-12 | 73,200 | +5.32% | 1,989,866 |
| 24-07-11 | 69,500 | -2.39% | 1,520,640 |
| 24-07-10 | 71,200 | +2.89% | 2,832,629 |
End-of-day quote Korea S.E., July 14, 2024
More quotes
Peptron, Inc. is a Korea-based company principally engaged in the development, manufacture and distribution of sustained-release medications. The Company mainly produces peptides as drug materials mainly for prostate cancer, hyperpituitarism, diabetes and neurodegenerative disorders. The Company also provides peptide synthesis services. The Company manufactures raw material medicines and some functional cosmetics. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +77.39% | 1.07B | |
| +20.63% | 127B | |
| +24.16% | 27.67B | |
| -20.17% | 20.33B | |
| -16.06% | 16.79B | |
| -18.07% | 15.63B | |
| -47.70% | 14.65B | |
| +11.92% | 14.84B | |
| +58.32% | 14.43B | |
| +149.98% | 12.49B |
- Stock Market
- Equities
- A087010 Stock
